During the past 2 years, substantial changes in the University of Hawai'i Cancer Center (UHCC) have been planned and implemented under the leadership of Dr. Carbone, with input from the EAB, Hawai'i Cancer Consortium (HCC) partners, senior leadership, as well as from the UHCC membership at large and ad hoc consultants. The key goals identified and attained during this period include formation of the HCC and transformation of the UHCC to a 501(c)3 entity and the building of a new Center to house the UHCC, to be opened November 2012. Further strengthening of current and future research have been implemented by the appointment of new leadership, faculty and support personnel such as grant writers, development of a common PRMS, DSM and IRB for the HCC, reorganization of the Shared Resources under the leadership of Dr. David Ward, reorganization of the Clinical Trials Office within Clinical Translation Research Services and substantially increasing grant funding and fund raising. Specifically, 11 new tenure track faculty with locus of tenure at UHCC and 2 tenure track faculty in joint recruitments with the Medical School and the School of Chemistry have been hired since 2009. Moreover, 18 new tenure track positions are available for recruitment. The faculty will be housed within the new UHCC building that is designed to host 43 independent investigators. Credentials of faculty recruits are reviewed by a Departmental Personnel Committee (DPC), which also oversees tenure and promotion applications as well as applications for membership in the UHCC. Their recommendations are forwarded to the Director for final decisions. Evaluation of the research, shared resources, administration and operating structure of both the UHCC and HCC undergo internal and external review. These include review by the University of Hawai'i President's Committee, consortium committees, the External Advisory Board and ad hoc consultants. An annual off-site faculty and staff retreat is also used as a venue to evaluate the scientific progress of each of the UHCC programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA071789-14W1
Application #
8736133
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
14
Fiscal Year
2013
Total Cost
$5,881
Indirect Cost
$1,986
Name
University of Hawaii
Department
Type
DUNS #
965088057
City
Honolulu
State
HI
Country
United States
Zip Code
96822
Huang, Brian Z; Le Marchand, Loic; Haiman, Christopher A et al. (2018) Atopic allergic conditions and pancreatic cancer risk: Results from the Multiethnic Cohort Study. Int J Cancer 142:2019-2027
Jenkins, Mark A; Win, Aung Ko; Templeton, Allyson S et al. (2018) Cohort Profile: The Colon Cancer Family Registry Cohort (CCFRC). Int J Epidemiol 47:387-388i
Naderi, Ali (2018) SRARP and HSPB7 are epigenetically regulated gene pairs that function as tumor suppressors and predict clinical outcome in malignancies. Mol Oncol 12:724-755
Franke, Adrian A; Li, Xingnan; Menden, Ariane et al. (2018) Oxytocin analysis from human serum, urine, and saliva by orbitrap liquid chromatography-mass spectrometry. Drug Test Anal :
Fanidi, Anouar; Muller, David C; Yuan, Jian-Min et al. (2018) Circulating Folate, Vitamin B6, and Methionine in Relation to Lung Cancer Risk in the Lung Cancer Cohort Consortium (LC3). J Natl Cancer Inst 110:
Rohrmann, Sabine; Shvetsov, Yurii B; Morimoto, Yukiko et al. (2018) Self-reported dietary flavonoid intake and serum markers of inflammation: the multiethnic cohort. Cancer Causes Control 29:601-607
Faouzi, Malika; Neupane, Ram P; Yang, Jian et al. (2018) Areca nut extracts mobilize calcium and release pro-inflammatory cytokines from various immune cells. Sci Rep 8:1075
Nishioka, Scott T; Sato, Miles M; Wong, Linda L et al. (2018) Clinical and molecular sub-classification of hepatocellular carcinoma relative to alpha-fetoprotein level in an Asia-Pacific island cohort. Hepatoma Res 4:
Marciel, Michael P; Rose, Aaron H; Martinez, Verena et al. (2018) Calpain-2 inhibitor treatment preferentially reduces tumor progression for human colon cancer cells expressing highest levels of this enzyme. Cancer Med 7:175-183
Shi, Geng-Xian; Yang, Won Seok; Jin, Ling et al. (2018) RSK2 drives cell motility by serine phosphorylation of LARG and activation of Rho GTPases. Proc Natl Acad Sci U S A 115:E190-E199

Showing the most recent 10 out of 562 publications